Takeda, Sumitomo End Latuda Pact in Europe
By

Sumitomo Dainippon Pharma Co., Ltd. and Takeda Pharmaceutical Company Limited have jointly announced that their license agreement entered into in March 2011 for the joint development and exclusive commercialization of pharmaceutical products containing lurasidone hydrochloride (Latuda), an atypical antipsychotic agent, in Europe, will be terminated. The companies are starting discussions in an effort to finalize and execute a mutual agreement establishing a transition plan for the orderly transfer of all development and commercialization rights and activities with respect to Latuda to Sumitomo Dainippon Pharma.

Takeda's right to develop and commercialize Latuda within 26 member states of the European Union (excluding the United Kingdom), Switzerland, Norway, Turkey and Russia, will transfer back to Sumitomo Dainippon Pharma upon the effective date of the termination.

The termination of the agreement is based on market and business considerations of Takeda and is not the result of new safety or efficacy information on Latuda. Sumitomo Dainippon Pharma and Takeda continue to believe that Latuda is an appropriate treatment option for adult patients with schizophrenia with minimal impact on important measures of metabolic health. Latuda has been available in the United States since 2011, in Canada since 2012, and subsequently in six countries in Europe. During this time it is estimated that more than one million patients have been treated with Latuda.

The termination of the agreement is expected to have minor impact on the consolidated business performance of Sumitomo Dainippon Pharma and Takeda in the fiscal year ending March 2016.

Latuda is an atypical antipsychotic developed originally by Sumitomo Dainippon Pharma, characterized by a unique chemical structure and an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, Latuda is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine or muscarinic receptors.

Latuda was approved for the treatment of schizophrenia in adults by the European Commission (EC) in March 2014 and Swiss Medic in August 2013. Latuda is currently available in Switzerland, Denmark, Norway, Finland, the Netherlands and the UK. Outside of Europe, Latuda is available in the USA and Canada for the treatment of schizophrenia and bipolar depression in adults. Latuda has also been approved in Australia for the treatment of schizophrenia in adults. Latuda has been available in the USA since 2011 and in Canada since 2012, in Switzerland since 2013, in Denmark, Norway and the UK since 2014, and in the Netherlands and Finland since 2015.

Source Takeda

Leave a Reply

Your email address will not be published. Required fields are marked *